MedTrace Logo

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

NCT07117890 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2025-12-24

No results posted yet for this study

Summary

This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

sunvozertinib 300mg

sunvozertinib monotherapy, 300mg QD

DRUG

sunvozertinib 200mg

sunvozertinib monotherapy, 200mg QD

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-07
Primary Completion
2027-02-20
Completion
2027-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07117890 on ClinicalTrials.gov